SOURCE: Cannabis Science, Inc.

Cannabis Science, Inc.

August 10, 2015 09:11 ET

Cannabis Science Research Foundation Releases Preliminary CBIS Products in California Dispensaries Beginning With at Least Three or Four Different Public and Private Locations With More Products and Dispensary Locations Expected to Be Reported on a Weekly Basis

COLORADO SPRINGS, CO--(Marketwired - Aug 10, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. Company specializing in cannabinoid based drug development, is proud to announce that the initial California products have been released through their agreement with the Cannabis Science Research Foundation. The initial release is for test marketing, and results will be used for additional large-scale rollouts. The CBIS Brand is being sold in multiple locations in California; there are currently at least three or four public and private dispensaries to acquire the products.

The website will be updated on a weekly basis as more California locations and more diverse CBIS Products come online. Current Public locations that CBIS California Products can be found are:

Hidden Leaf Organics
5009 Melrose Ave.
Los Angeles, CA 90038
323.822.5135

Cannacanhelp Inc (Formerly CCIC)
6614 Ave 304
Goshen, CA 93227
5596514090

"We have had previous success with self-medicated patient usage and we expect much of the same from this day forth. We have received plenty of requests from self-medicating patients worldwide looking for treatments for all types of critical ailments. We are just relieved to get these initial products out there to get self-medicating patient feedback. We have plenty of diverse products to be released for many different ailment situations, as each self-medicating patient has their unique needs and desires for their personal ailments. We will be releasing various product dosages, various delivery methodologies, in various jurisdictions as regulatory stipulations permit. We look forward to releasing more information about additional products and locations as the information becomes available. Please feel free to contact me directly with any questions and special requests; our team is ready," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder Cannabis Science Inc., and the Cannabis Science Research Foundation.

The California new product releases are due to Cannabis Science signing a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF is responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives. The CSRF license distribution agreement is required to accommodate the committed focus CBIS has on its FDA drug development programs.

Please visit:
http://cannabisscienceresearchfoundation.org
http://cannabisscienceresearchfoundation.org/research/product-research
http://pac.cannabisscienceresearchfoundation.org

About Cannabis Science Research Foundation
The Cannabis Science Research Foundation, a non-profit organization, is a new source of hope for a world where countless medical conditions affect millions of people in the United States alone. It is not just any foundation; it is an institute bringing new findings about the endocannabinoid system to light using state of the art research. The findings from the research will help guide the Foundation and its partners to develop new products, enter the FDA, and perform clinical studies.

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact Information